This 12-week , open-label , 4-way crossover , phase 1 study randomly assigned subjects to 1 of 4 treatment sequences - single oral dose OROS hydromorphone : 8 mg , 16 mg , 32 mg , or 64 mg - along with 50 mg naltrexone .